Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations down into almost value status. The reality is while there will continue to be populist political growling, many of the specialty companies focus on generics, which by design are cheaper than name brands.
